Latuda lurasidone regulatory update

Dainippon Sumitomo and partner Takeda said EMA accepted for review an MAA for lurasidone to treat schizophrenia. Takeda has exclusive rights from Dainippon to commercialize the product for schizophrenia and bipolar disorder in the EU, Norway, Russia, Switzerland and Turkey. Dainippon markets the product under the name Latuda in the U.S. and Canada for schizophrenia. ...